Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

ClinicalTrials.gov ID: NCT01722487

Public ClinicalTrials.gov record NCT01722487. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study identification

NCT ID
NCT01722487
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pharmacyclics LLC.
Industry
Enrollment
269 participants

Conditions and interventions

Interventions

  • Chlorambucil Drug
  • Ibrutinib Drug

Drug

Eligibility (public fields only)

Age range
65 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2013
Primary completion
Apr 30, 2015
Completion
Apr 30, 2015
Last update posted
Nov 29, 2017

2013 – 2015

United States locations

U.S. sites
22
U.S. states
15
U.S. cities
22
Facility City State ZIP Site status
Site Reference ID/Investigator #047 Duarte California 91010
Site Reference ID/Investigator #408 La Jolla California 92093
Site Reference ID/Investigator #720 Santa Rosa California 95403
Site Reference ID/Investigator #038 Stanford California 94305
Site Reference ID/Investigator #125 Atlanta Georgia 30318
Site Reference ID/Investigator #126 Chicago Illinois 60637
Site Reference ID/Investigator #071 Louisville Kentucky 40207
Site Reference ID/Investigator #307 Worcester Massachusetts 01655
Site Reference ID/Investigator #387 Ann Arbor Michigan 48109
Site Reference ID/Investigator #221 St Louis Missouri 63110
Site Reference ID/Investigator #712 Las Vegas Nevada 89169
Site Reference ID/Investigator #350 New Hyde Park New York 11042
Site Reference ID/Investigator #127 Rochester New York 14642
Site Reference ID/Investigator #656 Goldsboro North Carolina 27534
Site Reference ID/Investigator #734 Columbus Ohio 43219
Site Reference ID/Investigator #677 Portland Oregon 97227
Site Reference ID/Investigator #050 Pittsburgh Pennsylvania 15232
Site Reference ID/Investigator #032 Houston Texas 77030
Site Reference ID/Investigator #381 Laredo Texas 78041
Site Reference ID/Investigator #653 San Antonio Texas 78229
Site Reference ID/Investigator #404 Seattle Washington 98109
Site Reference ID/Investigator #731 Walla Walla Washington 99362

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01722487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 29, 2017 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01722487 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →